Therapeutics News and Research

RSS

Long non-coding RNA promotes melanoma cell survival and invasion

Traditionally, RNA was mostly known as the messenger molecule that carries protein-making instructions from a cell's nucleus to the cytoplasm. But scientists now estimate that approximately 97 percent of human RNA doesn't actually code for proteins at all. A flurry of research in the past decade has revealed that some types of non-coding RNAs switch genes on and off and influence protein function.

11 May 2011

Spinal manipulation as effective as microdiskectomy for patients with sciatica

In a recent study, "Manipulation or Microdisketomy for Sciatica? A Prospective Randomized Clinical Study," researchers concluded that spinal manipulation was just as effective as microdiskectomy for patients struggling with sciatica secondary to lumbar disk herniation.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting

Durata Therapeutics today announced surveillance data demonstrating potency of the Company's lead antibiotic product, dalbavancin, a long-acting, intravenous lipoglycopeptide, against a broad spectrum of gram-positive bacteria prevalent in recent years.

10 May 2011

HIV drugs can be used to target malaria and other parasitic diseases

Drugs used to treat HIV may form templates for lifesaving drugs targeted at malaria and other parasitic diseases, according to a new study from Cardiff University.

10 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

MGH, Duke University and Angion Biomedica partner to develop novel therapeutics for ischemic stroke

Angion Biomedica Corp. announced today the establishment of an alliance with Duke University and Massachusetts General Hospital to pursue advanced development and clinical studies of its lead therapeutics for treatment of ischemic stroke.

10 May 2011

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular, wound care and orthopedic areas, announced today its results for the first quarter ended March 31, 2011.

10 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

New international project to create more mutant genes, address shortage of Cre resources

Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.

9 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

The Centre for Drug Research and Development announced today the signing of affiliation agreements with both the University of Calgary and University Technologies International.

6 May 2011

Cell Therapeutics Board approves reverse stock split

Cell Therapeutics, Inc. today announced that the Company's Board of Directors approved a reverse stock split following the Company's receipt on May 3, 2011 of a notification of non-compliance from the staff of The NASDAQ Stock Market LLC.

6 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

The Center of Innovation for Nanobiotechnology (COIN) today announced the upcoming NanoBio Executive Roundtable event to be hosted at RTP Foundation in Durham, NC on May 17, 2011. This Roundtable will tackle regulatory issues surrounding nanomedicine commercialization. The “Nanomedicines and the Regulatory Path” Roundtable will kick off with a presentation from Katherine Tyner, Ph.D., a Chemist in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA).

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Therapeutics News and Research

Long non-coding RNA promotes melanoma cell survival and invasion

Spinal manipulation as effective as microdiskectomy for patients with sciatica

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Dalbavancin surveillance antibiotic results for Gram-positive pathogens presented at ECCMID meeting

HIV drugs can be used to target malaria and other parasitic diseases

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

MGH, Duke University and Angion Biomedica partner to develop novel therapeutics for ischemic stroke

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

Unigene first quarter net loss decreases 58% to $6.6 million

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

New international project to create more mutant genes, address shortage of Cre resources

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

Cell Therapeutics Board approves reverse stock split

Omeros' PDE7 program expands addiction franchise

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News